Page 5 - Laurus Labs

Nifty Pharma may have bottomed out; Aurobindo, Glenmark can rally up to 10%

The Nifty Pharma index has crossed its near-term resistance at 13,700, and may spurt another 1.5 per cent.

Laurus Labs surges 6% to hit over 4-month high

Analysts remain optimistic on the company's outlook for FY23 & FY24 with new capacity addition for commercial usage for FDF and API segments, ARV business and robust growth expected in CS business.

Laurus Labs up 8% in two days on purchase orders from global pharma company

The company on Thursday said it has received purchase orders from a leading global life sciences company and the supplies will commence from March 2022.

Laurus Labs bounces 16% from day's low on heavy volumes

The company said its Q3FY22 results were impacted by lower sales of ARV, APIs and formulations due to stocking at channel partners and it expects improvement from January-March quarter (Q4).

Buy these mid, smallcap stocks for at least 20% returns in 2022

Laurus Labs Ltd, Endurance Technologies Ltd may surge over 30 per cent whereas small cap stocks like Avanti Feeds Ltd, BASF India and Rain Industries could jump up to 40 per cent from current levels

Laurus Labs signs pact to acquire 26.62 % stake in ImmunoACT

Laurus labs investment in ImmunoACT is part of the larger strategy to strengthen biologics business of the firm

Adani Transmission, Max Financials, Laurus Labs to gain from FTSE rejig

The three stocks are part of several other domestic companies likely to get added to FTSE indices. Adani Transmission is likely to see the largest inflows at $121 million

Laurus Labs hits record high; rallies 17% in 7 days post Q1 results

The management holds a positive outlook across all four businesses -- FDF, APIs, Synthesis and Bio -- and believes the outlook remains robust driven by improving demand and supported by capex

Laurus Labs rebounds 9% from day's low after 3 straight sessions of decline

The management maintains positive outlook across all four businesses -- FDF, APIs, Synthesis and Bio-- on the back of improving demand, and supported by capacity expansion plans planned

Laurus Labs receives licence from DRDO to manufacture Covid drug 2DG

2DG has been given emergency approval by the Drugs Controller General of India (DCGI) for use on COVID-19 patients in the country, Laurus Labs said in a regulatory filing.

Prospects in key segments to keep Laurus Labs' growth trajectory strong

The stock has seen a six-fold jump in value over the last one year

Laurus Labs rallies 5% on credit rating upgrade; stock hits record high

The company is looking to build new capacities/facilities that would propel its growth in the coming years

Laurus Labs gains 2% on robust growth outlook, zooms 70% so far in FY22

The company is looking to build new capacities and facilities that would propel its growth in the coming years

Laurus Labs, Alkyl Amines: More steam left after 1,000% gain from 2020 low?

Laurus Labs is likely to maintain its upward journey as long as it doesn't break the support level of Rs 600 levels

Laurus Labs trades higher for 8th straight day, soars 73% in 3 months

Shares of Laurus Labs continued their upward journey to hit a new high of Rs 599 on the BSE in intra-day trade on Tuesday

Laurus Labs shares advance 5% on strong growth outlook

Laurus is well poised to follow the success story of some leading CDMO players backed by strong chemistry and integrated model

Laurus Labs hits new high in subdued market, surges 30% in a month

The company is scheduled to meet on April 29, 2021, to consider and approve the audited financial results of the company for the financial year ended March 31, 2021

Laurus Labs rallies 6%, hits record high on heavy volume

The pharmaceutical company's stock surpassed its previous high of Rs 386, touched on January 25, 2021

Dixon Tech, Adani Green: How to trade multi-baggers of FY21 in new fiscal

Hindustan Copper, Aarti Drugs, Dixon Technology, APL Apollo Tubes, Laurus Labs and Affle India, meanwhile, zoomed over 400 per cent during FY21

Laurus Labs falls 5% as promoters sell 1.3% stake in company

Laurus Labs said the significant part of the above amount shall be utilized to release the pledge on their equity shares of the company